GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » Degree of Operating Leverage

CARM (CARISMA Therapeutics) Degree of Operating Leverage : -1.20 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. CARISMA Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -1.20. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for CARISMA Therapeutics's Degree of Operating Leverage or its related term are showing as below:

CARM's Degree of Operating Leverage is ranked better than
73.98% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs CARM: -1.20

CARISMA Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for CARISMA Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Degree of Operating Leverage Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
- - - 1.02 -0.95

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 -0.04 -0.49 -0.95 -1.20

Competitive Comparison of CARISMA Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, CARISMA Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARISMA Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Degree of Operating Leverage falls into.


;
;

CARISMA Therapeutics Degree of Operating Leverage Calculation

CARISMA Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -52.003 (Mar. 2025) / -85.269 (Mar. 2024) - 1 )/( 19.964 (Mar. 2025) / 15.073 (Mar. 2024) - 1 )
=-0.3901/0.3245
=-1.20***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CARISMA Therapeutics  (NAS:CARM) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


CARISMA Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


CARISMA Therapeutics Business Description

Traded in Other Exchanges
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Executives
Modernatx, Inc. 10 percent owner 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky officer: Chief Scientific Officer C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales officer: Chief Development Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S. director C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake officer: Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu officer: Principal Accounting Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142